Cogent Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
COGT$31.64-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Series A Non-Voting Convertible PreferredStock · Series B Non-Voting Convertible PreferredStock · Common Stock · AdditionalPaid-in · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Shares · Amount · Capital · Income (Loss) · Deficit · Equity | |||||||||||
| Balances at December 31, 2023 | 74,465 | $60,035 | — | $— | 86,124,249 | $86 | $801,059 | $246 | $(603,624) | $257,802 | |
| Issuance of Series B non-voting convertible preferred stock and common stock, net of issuance costs of $11.6 million, in connection with the Private Placement | — | — | 12,280 | 87,364 | 17,717,997 | 18 | 126,034 | — | — | 213,416 | |
| Exchange of common stock for Series B non-voting convertible preferred stock | — | — | 8,300 | 74,754 | (8,300,000) | (8) | (74,746) | — | — | — | |
| Issuance of common stock under Employee Stock Purchase Plan | — | — | — | — | 71,150 | — | 356 | — | — | 356 | |
| Unrealized losses on marketable securities | — | — | — | — | — | — | — | (285) | (285) | ||
| Stock-based compensation expense | — | — | — | — | — | — | 9,393 | — | — | 9,393 | |
| Net loss | — | — | — | — | — | — | — | — | (58,348) | (58,348) | |
| Balances at March 31, 2024 | 74,465 | $60,035 | 20,580 | $162,118 | 95,613,396 | $96 | $862,096 | $(39) | $(661,972) | $422,334 | |
| Conversion of Series B non-voting convertible preferred stock into common stock | — | — | (13,712) | (107,980) | 13,712,000 | 13 | 107,967 | — | — | - | |
| Change in estimate on Private Placement issuance costs | — | — | — | (53) | — | — | (76) | — | — | (129) | |
| Issuance of common stock from exercises | — | — | — | — | 17,828 | — | 109 | — | — | 109 | |
| Unrealized losses on marketable securities | — | — | — | - | — | — | - | (153) | — | (153) | |
| Stock-based compensation expense | — | — | — | — | — | — | 10,012 | — | — | 10,012 | |
| Net loss | — | — | — | — | — | — | — | — | (58,950) | (58,950) | |
| Balances at June 30, 2024 | 74,465 | $60,035 | 6,868 | $54,085 | 109,343,224 | $109 | $980,108 | $(192) | $(720,922) | $373,223 | |
| Series A Non-Voting Convertible PreferredStock · Common Stock · AdditionalPaid-in · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances at December 31, 2022 | 81,050 | $65,830 | 69,893,434 | $70 | $601,153 | $(104) | $(411,214) | $255,735 |
| Conversion of Series A non-voting preferred stock into common stock | (4,000) | (3,520) | 1,000,000 | 1 | 3,519 | — | — | — |
| Issuance of common stock under Employee Stock Purchase Plan | — | — | 39,228 | — | 313 | — | — | 313 |
| Issuance of common stock upon exercise of stock options | — | — | 14,128 | — | 132 | — | — | 132 |
| Unrealized gains on marketable securities | — | — | — | — | — | 120 | — | 120 |
| Stock-based compensation expense | — | — | — | — | 5,850 | — | — | 5,850 |
| Net loss | — | — | — | — | — | — | (38,587) | (38,587) |
| Balances at March 31, 2023 | 77,050 | $62,310 | 70,946,790 | $71 | $610,967 | $16 | $(449,801) | $223,563 |
| Issuance of common stock in underwritten public offering, net of offering costs of 10.7 million | — | — | 14,375,000 | 14 | 161,775 | — | — | 161,789 |
| Issuance of common stock upon exercise of stock options | — | — | 12,375 | — | 102 | — | — | 102 |
| Unrealized losses on marketable securities | — | — | — | — | — | (113) | — | (113) |
| Stock-based compensation expense | — | — | — | — | 7,163 | — | — | 7,163 |
| Net loss | — | — | — | — | — | — | (44,076) | (44,076) |
| Balances at June 30, 2023 | 77,050 | 62,310 | 85,334,165 | 85 | 780,007 | (97) | (493,877) | 348,428 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.